Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print Cited Medium: Print ISSN: 0268-3369 (Print) Linking ISSN: 02683369 NLM ISO Abbreviation: Bone Marrow Transplant Subsets: MEDLINE
    • بيانات النشر:
      Publication: <2003->: London : Nature Publishing Group
      Original Publication: Basingstoke, Hampshire : Scientific & Medical Division, Macmillan Press, c1986-
    • الموضوع:
      Hematopoietic Stem Cell Transplantation/*methods ; Lymphoma/*therapy; Adult ; Aged ; Disease-Free Survival ; Female ; Graft vs Host Disease ; Graft vs Tumor Effect ; Humans ; Japan ; Lymphoma/mortality ; Male ; Middle Aged ; Multivariate Analysis ; Retrospective Studies ; Risk ; Stem Cell Transplantation ; Time Factors ; Treatment Outcome
    • نبذة مختصرة :
      We conducted a nation-wide survey of 112 adult Japanese patients who underwent reduced-intensity stem cell transplantation (RIST) from 1999 to 2002. Underlying diseases included indolent (n=45), aggressive (n=58) and highly aggressive lymphomas (n=9). Median age of the patients was 49 years. A total of 40 patients (36%) had relapsed diseases after autologous stem cell transplantation and 36 patients (32%) had received radiotherapy. RIST regimens were fludarabine-based (n=95), low-dose total body irradiation-based (n=6) and others (n=11). Cumulative incidences of grade II-IV acute graft-versus-host disease (GVHD) and chronic GVHD were, respectively, 49 and 59%. Cumulative incidences of progression and progression-free mortality were 18 and 25%, respectively. With a median follow-up of 23.9 months, 3-year overall survival rates were 59%. A multivariate analysis identified three significant factors for progression, which are history of radiation (relative risk (RR) 3.45, confidential interval (CI) 1.12-10.0, P=0.03), central nervous system involvement (RR 6.25, CI 2.08-20.0, P=0.001) and development of GVHD (RR 0.28, CI 0.090-0.86, P=0.026). RIST may have decreased the rate of transplant-related mortality, and GVHD may have induced a graft-versus-lymphoma effect. However, whether or not these potential benefits can be directly translated into improved patient survival should be evaluated in further studies.
    • الموضوع:
      Date Created: 20050607 Date Completed: 20050929 Latest Revision: 20050718
    • الموضوع:
      20250114
    • الرقم المعرف:
      10.1038/sj.bmt.1705027
    • الرقم المعرف:
      15937505